학술논문
New Targets and New Mechanisms in Lung Cancer.
Document Type
Article
Author
Source
Oncology (08909091); May2013, Vol. 27 Issue 5, p1-15, 15p
Subject
Language
ISSN
08909091
Abstract
The article discusses the new forms of chemotherapy and new treatment targets in lung cancer. It is mentioned that gefitinib and erlotinib bind in reverse to the adenosine triphosphate (ATP) binding site of epidermal growth factor receptor (EGFR) tyrosine kinase which initiates signaling cascades. It states that Anaplastic Lymphoma Kinase (ALK) is identified in anaplastic large cell lymphoma patients. Types of chemotherapies including immunotherapy and cytotoxic chemotherapy is also described.